肌萎缩侧索硬化
医学
疾病
病因学
SOD1
退行性疾病
临床试验
重症监护医学
神经科学
病理
生物
作者
Swati Dhasmana,Anupam Dhasmana,Acharan S. Narula,Meena Jaggi,Murali M. Yallapu,Subhash C. Chauhan
出处
期刊:Life Sciences
[Elsevier]
日期:2021-11-19
卷期号:288: 120156-120156
被引量:36
标识
DOI:10.1016/j.lfs.2021.120156
摘要
Amyotrophic lateral sclerosis (ALS) is a progressive and fatal neurological disease affecting both upper and lower motor neurons. In the United States alone, there are 16,000-20,000 established cases of ALS. The early disease diagnosis is challenging due to many overlapping pathophysiologies with other neurological diseases. The etiology of ALS is unknown; however, it is divided into two categories: familial ALS (fALS) which occurs due to gene mutations & contributes to 5-10% of ALS, and sporadic ALS (sALS) which is due to environmental factors & contributes to 90-95% of ALS. There is still no curative treatment for ALS: palliative care and symptomatic treatment are therefore essential components in the management of these patients. In this review, we provide a panoramic view of ALS, which includes epidemiology, risk factors, pathophysiologies, biomarkers, diagnosis, therapeutics (natural, synthetic, gene-based, pharmacological, stem cell, extracellular vesicles, and physical therapy), controversies (in the clinical trials of ALS), the scope of nanomedicine in ALS, and future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI